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Abstract Traditional risk charts for the prediction of car-
diovascular disease (CVD) include cholesterol parameters.
We evaluated how models predict fatal CVD when cholesterol
is replaced by glucose parameters. We used data from
NHANES III, a US survey conducted 1988–1994 (follow-up
until 2006); 15,454 participants (1,716 CVD deaths) were
included. Based on the ESC SCORE method, we used age,
sex, blood pressure, smoking and either of the following: (1)
total cholesterol, (2) total-to-HDL-cholesterol, (3) glucose,
(4) glycated hemoglobin (A1C). Scaled Brier score (BS),
Nagelkerke’s R2 (NR) and integrated discrimination
improvement (IDI) were used for model comparison. The
ranking (best to worst) was: A1C (BS = 11.62 %; NR =
0.0865; IDI = 0.0091), glucose (11.16 %; 0.0734; 0.0067),
total-to-HDL-cholesterol (9.97 %; 0.0547; 0.0010), choles-
terol (9.75 %; 0.0484; 0, reference). Differences between
models with cholesterol and glucose or A1C were statistically
significant. This study suggests the use of A1C instead of
cholesterol parameters in charts to assess CVD risk.
Keywords Glycated hemoglobin  Risk scores 
Risk prediction  Mortality
Abbreviations
CVD Cardiovascular disease
A1C Glycated hemoglobin
NHANES National Health and Nutrition Examination
Survey
Introduction
Estimating the individual risk of cardiovascular disease
(CVD) is traditionally based on age, sex, smoking status,
blood pressure and total cholesterol or total-to-HDL-cho-
lesterol. Derived risk prediction models and risk charts
include the Framingham Risk Score or, from Europe,
scores from Prospective Cardiovascular Mu¨nster Heart
Study (PROCAM) or SCORE (Systematic COronary Risk
Evaluation) [1–3]. Based on a large population sample
from Switzerland with long mortality follow-up, choles-
terol parameters contributed only little to prediction of
mortality risk [4]. Traditional risk scores have been
established decades ago. Meanwhile, new CVD risk factors
have emerged. There is increasing evidence for glucose
parameters being independent modifiable CVD risk factors
[5]. Based on SCORE and adhering to a maximum of five
variables displayed in the CVD risk chart, we used data
from NHANES III to compare the traditional prediction
model with models using glucose or glycated hemoglobin
(A1C) instead of cholesterol.
Methods
We used data from the US-based NHANES III (Third
National Health and Nutrition Examination Survey), con-
ducted 1988–1994 and with mortality follow-up until
December 31, 2006, originally including 20,050 individuals
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[6] (see Web Annex, Table 1). Analysis was restricted to
participants with all required variables (n = 15,454; 1,716
CVD deaths: ICD 9, 390–434; 436–459). We did not
explicitly exclude participants with pre-existing diseases,
but we performed sensitivity analyses without persons with
known diabetes and/or CVD (see Web Annex, Fig. 1 and 2).
Risk models were calculated with Weibull proportional
hazards regression with age as time variable and two strata
for sex [1]. Each of the four models included smoking status
(binary) and systolic blood pressure. As preliminary analyses
showed significant deviations from linearity, systolic blood
pressure was modelled as restricted cubic spline with five
knots (at 100, 113, 122, 135, 164 mmHg; see Web Annex,
Fig. 3 and 4). For completion, one of the following variables
was additionally included: total cholesterol, total-to-HDL-
cholesterol, glucose, A1C. A final model included both A1C
and cholesterol.
To compare the model fit, we used AIC, BIC and a
version of Nagelkerke’s R2 by Royston [7]. In order to
compare the predictive abilities of the models, we
Fig. 1 Chart for absolute 10-year risk of fatal cardiovascular disease
based on the model using A1C, 15,454participants of the NHANES
III study, 1988–1994. NHANES III: Third National Health and
Nutrition Examination Survey. Each risk percentage is calculated
using a combination of given risk factor values. For example, a man
aged 65, smoker, with a systolic blood pressure of 180 and a A1C of
9 % has an absolute risk (within the next 10 years) of fatal CVD of
30 %
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calculated the scaled mean cross-validated (leave-one-out)
Brier score [8, 9] and the integrated discrimination
improvement (IDI). A permutation test was used for the
comparison of Brier scores from different models, and a
Wald test was applied in the case of the IDI. The model
with cholesterol was used as reference. The Brier score
measures the mean squared difference between the risk
score and the actual outcome. The lower this deviation, the
better the respective risk prediction model. The Brier score
covers both calibration, i.e. the agreement of the prediction
with the true predictive distribution, and sharpness, i.e. the
precision of the predictive distribution. The IDI is a mea-
sure of improvement in model performance and represents
the difference in discrimination slopes of the competing
models.
Analyses were performed with STATA 11 (Stata Corp,
Texas, USA, 2009) and R (R Foundation for Statistical
Computing, version 2.14.1).
Fig. 2 Chart for absolute 10-year risk of fatal cardiovascular disease
based on the model using total cholesterol, 15,454 participants of the
NHANES III study, 1988–1994. NHANES III: Third National Health
and Nutrition Examination Survey. Each risk percentage is calculated
using a combination of given risk factor values. For example, a man
aged 65, smoker, with a systolic blood pressure of 180 and a total
cholesterol of 8 mmol/L has an absolute risk (within the next
10 years) of fatal CVD of 20 %
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Results
The predictive capacity of cholesterol and total-to-HDL-
cholesterol was not significantly different (Table 1).
Including cholesterol in addition to A1C did not improve
the predictions. Risk charts derived from the analyses are
shown in Figs. 1, 2. The A1C chart much better discrimi-
nated individuals with high and low CVD risk. Based on
A1C and cholesterol, respectively, 11.8 and 11.2 % of the
study population had a high CVD risk (C20 %). Glucose
and A1C predicted mortality significantly better than cho-
lesterol even after exclusion of persons with known dia-
betes or CVD (Web Annex, Fig. 1 and 2).
Discussion
Our comparisons based on data from NHANES III suggest
using A1C instead of cholesterol for CVD mortality risk
charts. As shown by others, A1C not only serves as a pre-
dictor of diabetes, it has also the ability to predict death from
CVD and from any cause and its predictiveness was better
than that of glucose [5]. Traditional risk models do not
consider glucose parameters as continuous variable. The
PROCAM and the Framingham models include information
about diabetes (yes/no) [2, 3] but this does not sufficiently
map the potential impact of blood glucose on CVD. With
dichotomization, mortality gradients below the threshold for
diabetes are missed, which wastes prevention potential. In
fact, excluding individuals with known diabetes only
marginally attenuated absolute risks (see Web Annex,
Fig. 1), suggesting that the A1C chart could also be used for
primary prevention. Mortality risk increases at A1C con-
centrations C5.7 %. This threshold is lower when other CVD
risk factors, e.g. high blood pressure or smoking, are present
[5, 10]. This is also suggested by the risk chart derived from
our analyses (Fig. 1).
One advantage of considering A1C in a continuous
(instead of a dichotomized) form is that the CVD risk chart
could be a tool for physicians helping to prevent or delay the
onset of diabetes in persons with prediabetes (A1C
5.7–6.4 %) potentially reducing morbidity and premature
death. The chart could be used to motivate individuals to
follow lifestyle recommendations and to improve compli-
ance. A1C can be lowered with physical activity, weight
management and healthy diet and, thus, opens doors for
lifestyle recommendations [11, 12]. Prediabetes can also be
effectively treated with Metformin which decreases the rate
of conversion from prediabetes to diabetes [11]. Caring for
persons early in the pathway to diabetes may be much more
effective than treating them once diabetes is established.
This is not possible when the risk associated with increased
A1C concentrations is only considered dichotomously. A1C
can easily and inexpensively be measured and also be
interpreted in the non-fasting state [5], thus facilitating
screening procedures. Our analyses do not suggest that
additional assessment of cholesterol parameters is necessary
for risk assessment. In contrast, relying on cholesterol
parameters only could mean to miss persons with increased
CVD risk. In hypercholesterolemic patients, CVD mortality
Table 1 Estimated coefficients of modifiable risk factors of selected models with comparison measures
Chart models (5 variables) Separate model
(6 variables)
Total cholesterol Total-to-HDL-
cholesterol
Glucose A1C A1C ? total
cholesterol
Current smoking (yes/no) 1.994 (1.760; 2.260) 1.990 (1.756; 2.255) 2.046 (1.806; 2.318) 2.011 (1.775; 2.279) 2.010 (1.774; 2.278)
Total cholesterol (mmol/L) 1.058 (1.013; 1.104) 1.045 (1.001; 1.090)
Total-to-HDL-
cholesterol (ratio)
1.073 (1.045; 1.102)
Glucose (mmol/L) 1.087 (1.070; 1.105)
Glycated hemoglobin
(A1C, %)
1.226 (1.186; 1.267) 1.223 (1.184; 1.264)
Model comparison
Scaled mean brier core 9.75 % 9.97 % 11.16 % 11.62 % 11.65 %
Nagelkerke’s R2 0.0484 0.0547 0.0734 0.0865 0.0879
AIC 2075 2057 2003 1965 1963
BIC 2152 2133 2079 2041 2047
Integrated discrimination
improvement (IDI)
0 (reference) 0.0010 (0.16) 0.0067 (\ 0.001) 0.0091 (\ 0.001) 0.0089 (\ 0.001)
Hazard ratios; figures in brackets are 95 % confidence intervals (coefficients) or p values (model comparison). Blood pressure was included as a
restricted cubic spline with five knots (100, 113, 122, 135, 164 mmHg); see Fig. 3 and 4 in the Web Annex
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could further be reduced with management of A1C [10]. This
is also suggested when comparing the respective risk charts.
However, whether reduction in A1C leads to a similar
reduction in CVD as with improvement of cholesterol
parameters (by lifestyle modification or medication) remains
to be elucidated.
We conclude that CVD risk assessment including A1C
may be superior to the traditional CVD risk chart with
cholesterol. This needs to be confirmed with other
populations.
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